Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19

Detalles Bibliográficos
Autores principales: Vityala, Yethindra, Tagaev, Tugolbai, Mamatov, Sagynali, Aidarov, Ziiabidin, Harinath, Panchadcharam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262423/
https://www.ncbi.nlm.nih.gov/pubmed/34169913
http://dx.doi.org/10.4103/ijp.IJP_33_21
_version_ 1783719187465633792
author Vityala, Yethindra
Tagaev, Tugolbai
Mamatov, Sagynali
Aidarov, Ziiabidin
Harinath, Panchadcharam
author_facet Vityala, Yethindra
Tagaev, Tugolbai
Mamatov, Sagynali
Aidarov, Ziiabidin
Harinath, Panchadcharam
author_sort Vityala, Yethindra
collection PubMed
description
format Online
Article
Text
id pubmed-8262423
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82624232021-07-16 Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19 Vityala, Yethindra Tagaev, Tugolbai Mamatov, Sagynali Aidarov, Ziiabidin Harinath, Panchadcharam Indian J Pharmacol Letter to the Editor Wolters Kluwer - Medknow 2021 2021-06-22 /pmc/articles/PMC8262423/ /pubmed/34169913 http://dx.doi.org/10.4103/ijp.IJP_33_21 Text en Copyright: © 2021 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Letter to the Editor
Vityala, Yethindra
Tagaev, Tugolbai
Mamatov, Sagynali
Aidarov, Ziiabidin
Harinath, Panchadcharam
Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title_full Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title_fullStr Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title_full_unstemmed Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title_short Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
title_sort potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262423/
https://www.ncbi.nlm.nih.gov/pubmed/34169913
http://dx.doi.org/10.4103/ijp.IJP_33_21
work_keys_str_mv AT vityalayethindra potentialeffectsofitolizumabtreatmentonplasmainterleukin6levelsinpatientswithseverecovid19
AT tagaevtugolbai potentialeffectsofitolizumabtreatmentonplasmainterleukin6levelsinpatientswithseverecovid19
AT mamatovsagynali potentialeffectsofitolizumabtreatmentonplasmainterleukin6levelsinpatientswithseverecovid19
AT aidarovziiabidin potentialeffectsofitolizumabtreatmentonplasmainterleukin6levelsinpatientswithseverecovid19
AT harinathpanchadcharam potentialeffectsofitolizumabtreatmentonplasmainterleukin6levelsinpatientswithseverecovid19

Ejemplares similares